White paper: „Good laboratory practice“

What is behind all this?

The “Good Laboratory Practice” regulatory mandate (GLP) was introduced in 1978 after the FDA (U.S. Food and Drug Administration) had already identified significant deficiencies in toxicological studies in the years preceding.

As a quality assurance system, it encompasses all organizational structures and the sequences of analyses and tests for approval of a medical product. Protection against the manipulation of raw data is a particularly important aspect of GLP, as manipulation would promote or accelerate approval. In this way, efforts could be made to ensure that the time and costs for the "non-clinical" studies were not in vain.

For this reason, GLP not only regulates the personnel, space and unit-specific requirements, but also the responsibilities during and after testing. And so the four eyes principle applies, meaning that several signatures are also required for the approval documents.
A scientific evaluation is only carried out upon approval, which is why it is necessary to submit all documents in their entirety. If documents are incomplete, approval is delayed or not granted, as missing documentation from analyses or testing is deemed to be non-existent at this point. It is therefore particularly important to submit all documents in their entirety to ensure approval.

Request the white paper now!

Fill out the form in order to receive the white paper free of charge.

Fields marked with * are mandatory

You can find our data privacy information here.

Content of the white paper:

  • Introduction to "good laboratory practice"
  • Organization
  • Operating procedures
  • GLP testing sequence
  • Approval